Trial Profile

A Phase I study of 4-(N-(S-penicillaminylacetyl)amino) phenylarsonous acid (PENAO) given as a continuous intravenous infusion, to patients with advanced solid tumours

Status: Discontinued

Phase of Trial: Phase I

Latest Information Update: 13 Sep 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs PENAO (Primary)
Indications Adenoid cystic carcinoma; Anal cancer; Astrocytoma; Bladder cancer; Carcinoma; Cervical cancer; Cholangiocarcinoma; Colorectal cancer; Gallbladder cancer; Malignant melanoma; Meningioma; Myxoid liposarcoma; Nasopharyngeal cancer; Neurilemmoma; Neuroblastoma; Ovarian cancer; Renal cell carcinoma; Solid tumours; Thyroid cancer
Focus Adverse reactions; First in man

Most Recent Events

03 Feb 2021 Results presented in the Beroni Group Media Release
04 Sep 2012 Status changed from planning to recruiting.
04 Sep 2012 New source identified and integrated: Australian New Zealand Clinical Trials Registry record ACTRN12612000908831.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com